Navigation Links
Aflac Announces Resignation of U.S. Marketing Officer
Date:10/2/2007

COLUMBUS, Ga., Oct. 2 /PRNewswire-FirstCall/ -- Aflac today announced that Jeffrey M. Herbert has resigned as senior vice president and chief marketing officer of the company's U.S. insurance operation. Herbert joined Aflac in October 2006 and cited personal reasons for his departure from the company.

(Logo: http://www.newscom.com/cgi-bin/prnh/20041202/CLTH019LOGO )

Commenting on Herbert's resignation, Aflac president and chief operating officer for Aflac U.S., Paul S. Amos II stated: "Although Jeff's tenure with Aflac was short, we are appreciative of his contributions to our company, and we wish him the best in his future endeavors.

"When we hired Jeff a year ago, we did so after deciding to split the senior level responsibilities of marketing and sales. We still believe that is an effective organization for our business and to that end, we will begin an immediate search for a replacement to work closely with our director of sales, Ron Kirkland. Due in great part to Ron's effective leadership of our sales force, I believe we are on track to achieve our sales targets for the year, and I believe 2007 will be another record year for Aflac U.S."

For more than 50 years, Aflac products have given policyholders the opportunity to direct cash where it is needed most when a life-interrupting medical event causes financial challenges. Aflac is the number one provider of guaranteed-renewable insurance in the United States and the number one insurance company in terms of individual insurance policies in force in Japan. Our insurance products provide protection to more than 40 million people worldwide. Aflac has been included in Fortune magazine's listing of America's Most Admired Companies for seven consecutive years and in Fortune magazine's list of the 100 Best Companies to Work For in America for nine consecutive years. Aflac has also been recognized three ti
'/>"/>

SOURCE Aflac
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine news :

1. PM announces a new health care order for India
2. Ramdoss Announces Introduction of RCH-II
3. Britain Announces Third Transfusion Related Mad Cow Case
4. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
5. Tibet Announces the Dalai Lama’s Tour of South Americ
6. NHS announces further Cost cutting Measures
7. Indian PM Announces Of Setting Up India Study Center At Tashkent
8. PowderMed Announces Needle-Less Flu Vaccine
9. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
10. Australian Government Announces Survey To Tackle Childhood Obesity
11. New Zealand Announces 10-year Plan For Betterment Of Mental Health Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2008)...ng point for behavior change, DES MOINES, Iowa, O...,Americans (51 percent) believe there are good thi...r changes are needed, according to the 2008,EBRI H...oday by the,Employee Benefit Research Institute an...derwritten by the Principal Financial Group(R)., ...
(Date:10/10/2008)...dentialing Center (ANCC) has designated Geisinger ...s came via a conference call to hospital administr...and applause., GMC joins an elite group of only 1...n the United States that have achieved Magnet stat...s recognition., "Achieving Magnet designation is ...
(Date:10/10/2008)... blame , , FRIDAY, Oct. 10 (HealthDay Ne...ve diabetes, being depressed was associated with a..., Publishing in the October issue of the Journal...he University of Washington tracked 10,704 Medicar...d diabetes and were enrolled in a disease manageme...
(Date:10/10/2008)...llence in the implementation of electronic health ...agement Systems Society (HIMSS) announces the reci...onal, Ambulatory and Community Health Organization...L (PRWEB) October 10, 2008 -- Honoring excellence ... (EHRs), the Healthcare Information and Managemen...
Breaking Medicine News(10 mins):Health News:Video: Just What the Doctor Ordered: Survey Shows Americans Adopting Healthier Lifestyles 2Health News:Video: Just What the Doctor Ordered: Survey Shows Americans Adopting Healthier Lifestyles 3Health News:Geisinger Medical Center earns prestigious Magnet designation 2Health News:Older Diabetics With Depression Face Higher Death Rate 2Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 2Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 3Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 4Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 5
...a routine dental check-up may not only prevent the...nalysis says that such screenings could end up sav...in healthcare costs for the patients. The review ...alth Technology Assessment, the international jour...
... are pretty much of a household therapy in the Uni...has revealed that these therapies have added value...ing the quality of life. In that respect, United K... health investment. “The conclusion is that if yo...
...at the University of California, San Francisco (UC... prevents the growth of brain cancer. // The compo...ate against lethal brain tumor. In animal studies ... to be potent against proliferating cancer cells. ...
... when uou're 80 years old or more might be quite b...s from a joint UC Irvine and University of Souther... mortality rates from participants of a large-scal... California retirement community. The analysis fo...
Other Medicine News:Health News:Routine Dental Check-Ups Should Include Oral Cancer Screening 2Health News:Varicose Vein Treatments Turn Out To Be A Viable Health Investment 2Health News:Varicose Vein Treatments Turn Out To Be A Viable Health Investment 3Health News:PI-103 Effective against Brain Cancer 2Health News:PI-103 Effective against Brain Cancer 3Health News:Elderly and Overweight -Not Such a Bad Combination After All 2
(Date:10/8/2008)...e, Oct. 8 /- Vical Incorporated (Nasd...data and new nonclinical data,demonstrating that t...applicable in DNA- and protein-based infectious di...Alain P. Rolland, Pharm.D., Ph.D., Vical,s,Senior ...t the data today,Wednesday, October 8, at the Wor...
(Date:10/7/2008)...as, Oct. 7 /- The Texas Cardiac Arrhy...er has been selected as one of,only a few sites in...ical,trial for a new device to treat persistent at...t, training and research center specializing in he... David,s Medical Center and,Texas Cardiovascular C...
(Date:10/7/2008)...al study of adults, VYVANSE taken once-daily signi...week, PHILADELPHIA, Oct. 7 /PRNewswire-FirstCall/...l specialty biopharmaceutical company, today,annou... of the Journal of,Clinical Psychiatry found once-...icit Hyperactivity Disorder (ADHD) symptoms in adu...
(Date:10/7/2008)...tracts highlighting CIMZIA,s long-term benefits an...ents presented at American College,of Gastroentero...tCall/ -- Data from two studies,presented this wee...gy,(ACG) Annual Meeting demonstrate that CIMZIA(R)...F alpha (Tumor Necrosis Factor alpha) - provides,s...
Breaking Medicine Technology:Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5Texas Cardiac Arrhythmia Institute at St. David's Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation 2Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 2Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 3Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 4Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 5Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 6CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 2CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 3CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 4CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 5CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 6CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 7CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 8CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 9New study sheds light on Gal 26 23225 3Bpagos hawk evolutionary history 641 1New study sheds light on Gal 26 23225 3Bpagos hawk evolutionary history 641 2First significant genetic finding in severe PMS or PMDD 2600 1First significant genetic finding in severe PMS or PMDD 2600 2Algorithms to reanimate the heart 2598 1Algorithms to reanimate the heart 2598 2Algorithms to reanimate the heart 2598 3Dietary calcium could possibly prevent the spread of breast cancer to bone 639 1Dietary calcium could possibly prevent the spread of breast cancer to bone 639 2
...SINESS WIRE)--Jun 25, 2007 - Neurogen,Corporation ...esults from two dose-ranging, Phase 2b clinical tr...,s proprietary insomnia agent,NG2-73, an alpha-3 ...lations were studied in each trial to determine th...ntenance of sleep,through the night without residu...
...hly potent DPP-4 inhibitor, possessing Ki of 27,pM...armaceuticals,Inc., a privately held drug discove...results of its potent, smart DPP-4 inhibitor,ARI-...n Diabetes,Association meeting in Chicago, Illinoi...y long acting, potent inhibitor of DPP-4 and,produ...
Other Medicine Technology:Neurogen Announces Positive Results for Proprietary Insomnia Drug,in Two Chronic Insomnia Clinical Trials 2Neurogen Announces Positive Results for Proprietary Insomnia Drug,in Two Chronic Insomnia Clinical Trials 3Neurogen Announces Positive Results for Proprietary Insomnia Drug,in Two Chronic Insomnia Clinical Trials 4Neurogen Announces Positive Results for Proprietary Insomnia Drug,in Two Chronic Insomnia Clinical Trials 5Neurogen Announces Positive Results for Proprietary Insomnia Drug,in Two Chronic Insomnia Clinical Trials 6Neurogen Announces Positive Results for Proprietary Insomnia Drug,in Two Chronic Insomnia Clinical Trials 7Neurogen Announces Positive Results for Proprietary Insomnia Drug,in Two Chronic Insomnia Clinical Trials 8Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4,Inhibitor, ARI-2243, at the ADA 2Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4,Inhibitor, ARI-2243, at the ADA 3Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4,Inhibitor, ARI-2243, at the ADA 4
Our Osteomark® ELISA kits provide a quantitative measurement of cross-linked N-telopeptides of type I collagen (NTx) as an indicator of bone resorption, with higher levels in serum or urine sampl
...B®) Test is a clinical chemistry assay that de...uring the cobalt binding capacity of albumin in a ...y 1990s, IMA is produced when circulating albumin .... During ischemia, the N-terminus of albumin is al...
...une testing feature single-well ANA screen and ENA...ncluding dsDNA, and 6 individual ENA kits: Sm, Sm/...ition, our autoimmune ELISA family includes a full..., Thyroglobulin, Thyroid Microsomal, MPO, PR3, Rhe...
... Diagnostics is a leading provider of immunofluore...menu that includes kits for autoimmune diseases, i...us conjugates and components. Our Impact IFA Test ...nd kit sizes to choose from. Kit components includ...
Medicine Products: